Rep. Jared Moskowitz Sells Shares of STERIS plc (NYSE:STE)

Representative Jared Moskowitz (Democratic-Florida) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 13th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of W.W. Grainger (NYSE:GWW) on 7/13/2026.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 7/13/2026.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 6/18/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of HCA Healthcare (NYSE:HCA) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of Monster Beverage (NASDAQ:MNST) on 6/17/2026.
• Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 6/12/2026.

STERIS Trading Up 0.4%

STE stock opened at $230.56 on Thursday. The company’s 50-day simple moving average is $224.83 and its 200-day simple moving average is $222.42. The company has a quick ratio of 1.35, a current ratio of 1.91 and a debt-to-equity ratio of 0.23. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The firm has a market cap of $22.48 billion, a P/E ratio of 28.19 and a beta of 0.91.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. The company had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%.STERIS’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.34 EPS. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. As a group, equities analysts forecast that STERIS plc will post 11.09 EPS for the current fiscal year.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.63. STERIS’s dividend payout ratio is 33.74%.

Analyst Ratings Changes

STE has been the topic of a number of research reports. UBS Group decreased their price target on shares of STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. KeyCorp dropped their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen raised STERIS from a “hold” rating to a “buy” rating in a research note on Sunday, August 9th. Weiss Ratings restated a “hold (c)” rating on shares of STERIS in a report on Monday, August 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $271.33.

Insiders Place Their Bets

In other news, VP John Adam Zangerle sold 1,419 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the transaction, the vice president owned 35,259 shares in the company, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 1,374 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at $13,493,164. This trade represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,851 shares of company stock valued at $1,545,052 in the last ninety days. Insiders own 1.12% of the company’s stock.

Institutional Trading of STERIS

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Activest Wealth Management increased its stake in STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in STERIS during the 4th quarter worth approximately $28,000. Western Wealth Management LLC purchased a new stake in shares of STERIS in the 1st quarter valued at approximately $25,000. Cornerstone Planning Group LLC raised its holdings in shares of STERIS by 342.3% in the 4th quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 89 shares in the last quarter. Finally, Elevation Wealth Partners LLC grew its stake in shares of STERIS by 1,130.0% during the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 113 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.